Reference is made to stock exchange announcements by Serendex Pharmaceuticals A/S in connection with the approved prospectus for the Rights Issue dated 10 December 2015 and the supplement prospectus for the Rights Issue dated 21 December 2015.

In connection with the Rights Issue, the following primary insiders were allocated shares:

Karin Verland (Chairman) was allocated 338,890 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mrs. Verland own a total of 350,000 shares in Serendex Pharmaceuticals A/S, corresponding to 0.21% of the share capital.

Christian Vinding Thomsen (board member), was allocated 50,000 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mr. Thomsen own a total of 50,000 shares in Serendex Pharmaceuticals A/S, corresponding to 0.03% of the share capital.

Don deBethizy (board member), was allocated 300,000 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mr. deBethizy own a total of 300,000 shares in Serendex Pharmaceuticals A/S, corresponding to 0.18% of the share capital.

Lorentz Jørgensen (board member), through his wholly owned company Sorana A/S, was allocated 128,587,034 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mr. Jørgensen and his related parties control 136,972,998 shares, corresponding to 83.47% of the share capital.

Tone Bjørnov (board member) was allocated 66,000 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights Issue, Mrs. Bjørnov own a total of 67,110 shares in Serendex Pharmaceuticals A/S, corresponding to 0.04% of the share capital.

Søren Bech Justesen (CFO) was allocated 86,120 shares in the Rights Issue at a price of NOK 0.75 per share. Following the Rights issue, Mr. Justesen own a total of 100,000 shares in Serendex Pharmaceuticals A/S, corresponding to 0.06% of the share capital.

Issuer
Serendex Pharmaceuticals A/S

ISIN-code
DK0060563427
('SENDEX')

Security
Shares

Market
Oslo Axess

For downolad 06 January 2016 Primary insider notification

For further information, please contact :

Søren Bech Justesen, CFO
Mobile +45 2911 0025
E-mail: sbj@serendex.com

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess. Please visitwww.serendex.com to learn more.

Serendex Pharmaceuticals A/S issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 06:09:03 UTC

Original Document: http://www.serendex.com/primary-insider-notification-7/